Long-term Complications of Hemodialysis
Keywords:
Hemodialysis, Hypotension, Muscle cramps, Infection transmission, Amyloidosis, HD complicationsAbstract
Hemodialysis is one of the renal replacement therapies, besides peritoneal dialysis and renal transplantation. Although hemodialysis can improve morbidity and mortality in renal patients, it has many complications that occur during the dialysis sessions and/or as long term use of hemodialysis. Hypotension, hypoglycemia, electrolyte disturbances, disequilibrium syndrome, hypocalcaemia etc are common complications occur during dialysis. In long-term dialysis, there are complications as amyloidosis, bone disease, endocrine disturbances, infection, cardiovascular complications, vascular access and nutrition complication. Important long-term hemodialysis complications will be reviewed in this article.
Downloads
References
Locatelli F, Manzoni C, Del Vecchio L, Di Filippo S. Changes in the clinical condition of haemodialysis patients. J Nephrol 1999; 12(Suppl 2):82-91
Blagg R C. Long-term Complications in Hemodialysis. SJKDT 2001; 12: 487-493.
Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 1998;32:853-906.
Liu JY, Birkmeyer NJ, Sanders JH, Morton JR, Henriques HF, Lahey SJ, Dow RW. Risks of morbidity and mortality in dialysis patients undergoing coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group. Circulation 2000;102:2973-7.
Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996;49:1379-85.
Raggi P. Detection and quantification of cardiovascular calcifications with electron beam tomography to estimate risk in hemodialysis patients. Clin Nephrol 2000;54: 325-33.
Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerik A, Greaser L, Elashoff RM, Salusky BI. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-83.
Isotalo PA, Halil A, Green M, Tang A, Lach B, Veinot JP. Metastatic calcification of the cardiac conduction system with heart block: an under-reported entity in chronic renal failure patients. J Forensic Sci 2000; 45:1335-8.).
Mocks J. Cardiovascular mortality in hemodialysis patients treated with epoetin beta-a retrospective study. Nephron 2000; 86:455-62.
Oda H, Keane WF. Lipid abnormalities in end stage renal disease. Nephrol Dial Transplant 1998;13(Suppl 1):45-9.
Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15.
Kronenberg F, Utermann G, Dieplinger H. Lipoprotein(a) in renal disease. Am J Kidney Dis 1996;27:1-25.
Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993;21:573-92.
Van Guldener C, Robinson K. Homocysteine and renal disease. Semin Thromb Hemost 2000;26:313-24.
Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26.
Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney Int 2001;59:407-14.
Orth S, Ogata H, Ritz E. Smoking and the kidney. Nephrol Dial Transplant 2000;15: 1509-11.
Scribner BH. Can antihypertensive medication control BP in hemodialysis patients: yes or no? Nephrol Dial Transplant 1999; 14:2599-601.
Charra B, Bergstrom J, Scribner BH. Blood pressure control in the dialysis patients: importance of the lag phenomenon. Am J Kidney Dis 1998;32: 720-4.
Charra B, Calemard M, Laurent G. Importance of treatment time and blood pressure control in achieving long-term survival on dialysis. Am J Nephrol 1996;16:35-44.
Baigent C, Wheeler D. Should we reduce blood cholesterol to prevent cardiovascular disease among patients with chronic renal failure? Nephrol Dial Transplant 2000;15: 1118-9.
Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000, 356:1213-1218.
Mune M, Yukawa S, Kishino M, et al. Effect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients. Kidney Int Suppl 1999;71:126-9.
Vaitkus P. Current status of prevention, diagnosis, and management of coronary artery disease in patients with kidney failure. Am Heart J 2000;139;1000-8.
Kay J, Bardin T. Osteoarticular disorders of renal origin: disease-related and iatrogenic. Baillieres Best Pract Res Clin Rheumatol 2000;14:285-305.
Floege J, Ketteler M. Beta2-microglobulinderived amyloidosis: an update. Kidney Int 2001;59(Suppl 78):S164-71.
Bardin T; Lebail-Darné JL; Zingraff J; Laredo JD; Voisin MC; Kreis H; Kuntz D. Dialysis arthropathy: outcome after renal transplantation. Am J Med 1995;99:243-8.
Locatelli F, Mastrangelo F, Redaelli B, Ronco C, Marcelli D, Orlandini Gand the Italian Cooperative Dialysis Study Group. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. Kidney Int 1996;50:1293–302.
Chertow GM, Plone M, Dillon MA, Burke SK, Slatapolsky E. Hyperparathyroidism and dialysis vintage. Clin Nephrol 2000;54:295-300.
Cannata JB. Adynamic bone and chronic renal failure: An overview. Am J Med Sci 2000;320:81-4.
Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000;36:1115-21.
Marcen R, Teruel JL, de la Cal MA, Gamez C. Spanish Cooperative Study of Nutrition in Hemodialysis. The impact of malnutrition in morbidity and mortality in stable haemodialysis patients. Nephrol Dial Transplant 1997;12:2324-31.
Combe C, Chauveau P, Laville M, Fouque D, Azar R, Cano N, Canaud B, Roth H, Leverve A. Influence of nutritional factors and hemodialysis adequacy on the survival of 1,610 French patients. Am J Kidney Dis 2001;37(Suppl 2):81-8.
Fukagawa M, Akizawa T, Kurokawa K. Is aplastic osteodystrophy a disease of malnutrition? Current Opin Nephrol Hypertens 2000; 9:363-7.
Zima T, TesaOV, Mestek O, NLimeLek K. Trace elements in end-stage renal disease: Clinical implications of trace elements. Blood Purif 1999;17:187-98.
NKF-DOQI. Clinical practice guidelines for vascular access. New York. National Kidney Foundation 1997:69.
Ellis PA, Reddy V, Bari N, Cairns HS. Late referral of end-stage renal failure. QJM 1998; 91:727-32.
Roubicek C, Brunet P, Huiart L, Thirion X, Leonetti F, Dussol B, Jaber K, Andrieu D, Ramananarivo P, Berland Y: Timing of nephrology referral: influence on mortality and morbidity. Am J Kidney Dis 36: 35-41, 2000
Woods JD, Port FK, Orzol S, Buoncristiani U, Young E, Wolfe RA, Held PJ. Clinical and biochemical correlates of starting “daily” hemodialysis. Kidney Int 1999; 55: 2467-76.
Zahedi MJ, Darvish Moghadam S, Alavian SM, Dalili M. Seroprevalence of hepatitis viruses B, C, D and HIV infection among hemodialysis patients in kerman province, South-East Iran. Hepat Mon. 2012;12(5):339-42
Elamin S, Abu-Aisha H. Prevention of hepatitis B virus and hepatitis C virus transmission in hemodialysis centers: review of current international recommendations. Arab J Nephrol Transplant. 2011;4(1):35-47.
Alavian SM, Einollahi B, Hajarizadeh B, Bakhtiari S, Nafar M, Ahrabi S. Prevalence of hepatitis C virus infection and related risk factors among Iranian haemodialysis patients. Nephrology (Carlton). 2003;8(5):256-06.
Assarehzadegan MA, Shakerinejad G, Noroozkohnejad R, Amini A, Rahim Rezaee SA. Prevalence of hepatitis C and B infection and HC V genotypes among hemodialysis patients in Khuzestan province, southwest Iran. Saudi J Kidney Dis Transpl. 2009;20(4):681-4.
Alavian SM, Kabir A, Ahmadi AB, Lankarani KB, Shahbabaie MA, Ahmadzad-Asl M. Hepatitis C infection in hemodialysis patients in Iran: a systematic review. Hemodial Int. 2010;14(3):253-62.
Kafi-abad SA, Rezvan H, Abolghasemi H, Talebian A. Prevalence and trends of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among blood donors in Iran, 2004 through 2007. Transfusion. 2009;49(10):2214-20.
El-kader YE-OA, Elmanama AA, Ayesh BM. Prevalence and risk factors of hepatitis B and C viruses among haemodialysis patients in Gaza strip, Palestine. Virol J. 2010;7:210.
Selm SB. Prevalence of hepatitis C virus infection among hemodialysis patients in a single center in Yemen. Saudi J Kidney Dis Transpl. 2010;21(6):1165-8.
Al-Jamal M, Al-Qudah A, Al-Shishi KF, Al-Sarayreh A, Al-Quraan L.Hepatitis C virus (HCV) infection in hemodialysis patients in the south of Jordan. Saudi J Kidney Dis Transpl. 2009;20(3):488-92.
Othman B, Monem F. Prevalence of antibodies to hepatitis C virus among hemodialysis patients in Damascus, Syria. Infection. 2001;29(5):262-5.
Khaja M, Hussain M, Farees N, Krishnan S, Habibullah C. Hepatitis B and C virus infection in chronic renal failure (CRF) patients. J Gastroenterol Hepatol 2002; 17(suppl): A 360.).
Pujol FH, Ponce JG, Lema MG, Capriles F, Devesa M, Sirit F. High incidence of hepatitis C virus infection in hemodialysis patients in units with high prevalence. J din Microbiol 1996;34:1633-6.
Kashem A, nusairat I, Mohammad M, Ramzy M, Nemma J, Karim MR, Divakaran MP, Tayaab AS. Hepatitis C virus among hemodialysis patients in Najran: prevalence is more among multicenter visitors. Saudi J Kidney Dis Transplant 2003;14:206-11.
Ambuhl PM, Binswanger U, Renner EL. Epidemiology of chronic hepatitis B and C among dialysis patients in Switzerland. Schweiz Med Wochenscber 2000; 130: 341-8.
Saune K, Kamar N, Miedouge M, Weclawiak H, Dubois M, Izopet J, , Dubois M, Izopet J, Rostaing L. . Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. Nephrol Dial Transplant. 2011;26(7):2309-16.
Gul A, Iqbal F. Prevalence of hepatitis C in patients on maintenance hemodialysis. J Coll Physician Surg Pak 2003; 13: 15-8.
Khameneh ZR, Sepehrvand N. Survey of hepatitis B status in hemodialysis patients in a training hospital in Urmia, Iran. Saudi J Kidney Dis Transpl. 2008;19(3):466-9.
Merat S, Rezvan H, Nouraie M, Jamali A, Assari S, Abolghasemi H, Radmard AR, Zaer-Rezaii H, Zeid-Abadi-Nejhad M, Hosseini MR, Amini-Kafiabad S, Maghsudlu M, Pourshams A, Malekzadeh R. The prevalence of hepatitis B surface antigen and anti hepatitis B core antibody in Iran: a population-based study. Arch Iran Med. 2009;12(3):225-31
Aghakhani A, Banifazl M, Kalantar E, Eslamifar A, Ahmadi F, Razeghi E, Atabak S, Amini M, Khadem-Sadegh A, Ramezani A. Occult hepatitis B virus infection in hemodialysis patients with isolated hepatitis B core antibody: a multicenter study. Ther Apher Dial. 2010; 14(3):349– 53.
Giatras I, Lau J, Levey AS. Effect of angiotensin-converting-enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med 1997;127:337-45.
Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA. Cardiac risk factors and the use of cardio-protective medications in patients with chronic renal insufficiency. Am J Kidney Dis 2001;37:484-9.
Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a metaanalysis. Ann Intern Med 1996;124:627-32.
Trocha AK, Schmidtke C, Didjurgeit U, Mühlhauser I, Bender R, Berger M. Effects of intensified antihypertensive treatment in diabetic nephropathy: mortality and morbidity results of a prospective controlled 10-year study. J Hypertens. 1999;17:1497-503.
Fink J, Blahut S, Reddy M, Light P. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 2001;37:348-55.
Hebert LA, Wilmer WA, Falkenhain ME, Ladson-Wofford SE, Nahman NS Jr, Rovin BH. Renoprotection: One or many therapies? Kidney Int 2001;59:1211-26.
Zahedi MJ, Darvish Moghadam S, Alavian SM, Dalili M. Seroprevalence of hepatitis viruses B, C, D and HIV infection among hemodialysis patients in kerman province, South-East Iran. HepatMon. 2012;12(5):339-42.
Downloads
Published
Issue
Section
License
This article is published open access under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0). You may copy, redistribute, adapt and build upon it for non-commercial purposes, provided you credit the authors, cite the original publication in the Journal of Medical Sciences with its DOI, indicate any changes, and distribute any adaptations under the same licence. Copyright rests with the authors. For commercial reuse, please contact the corresponding author. Full terms: https://sebhau.edu.ly/journal/joms/copyright-licensing
